• Early enrichment of ESR1 mutations and the impact on gene expression in pre-surgical primary breast cancer treated with aromatase inhibitors. 

  Leal, MF; Haynes, BP; Schuster, EF; Yeo, B; Afentakis, M; Zabaglo, L; Martins, V; Buus, R; Dodson, A; Cheang, MCU; Smith, IE; Martin, L-A; Dowsett, M (2019-09-23)

  PURPOSE: To investigate the presence of ESR1 mutation in primary oestrogen-receptor positive breast cancer (ER+BC) treated with extended (>4 weeks) neoadjuvant (pre-surgical) aromatase inhibitor (NAI) therapy and to identify ...
• The EORTC QLQ-C30 summary score as prognostic factor for survival of cancer patients in the “real-world”: Results from the population-based PROFILES registry 

  Husson, O
• A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. 

  George, SL; Izquierdo, E; Campbell, J; Koutroumanidou, E; Proszek, P; Jamal, S; Hughes, D; Yuan, L; Marshall, LV; Carceller, F; Chisholm, JC; Vaidya, S; Mandeville, H; Angelini, P; Wasti, A; Bexelius, T; Thway, K; Gatz, SA; Clarke, M; Al-Lazikani, B; Barone, G; Anderson, J; Tweddle, DA; Gonzalez, D; Walker, BA; Barton, J; Depani, S; Eze, J; Ahmed, SW; Moreno, L; Pearson, A; Shipley, J; Jones, C; Hargrave, D; Jacques, TS; Hubank, M; Chesler, L (2019-09-11)

  BACKGROUND: For children with cancer, the clinical integration of precision medicine to enable predictive biomarker-based therapeutic stratification is urgently needed. METHODS: We have developed a hybrid-capture next-generation ...
• In vivo modelling of chemo-resistant neuroblastoma provides new insights into chemo-refractory disease and metastasis. 

  Yogev, O; Almeida, GS; Barker, KT; George, SL; Kwok, C; Campbell, J; Zarowiecki, M; Kleftogiannis, D; Smith, LM; Hallsworth, A; Berry, P; Möcklinghoff, T; Webber, HT; Danielson, LS; Buttery, B; Calton, EA; da Costa, BM; Poon, E; Jamin, Y; Lise, S; Veal, GJ; Sebire, N; Robinson, SP; Anderson, J; Chesler, L (2019-08-12)

  Neuroblastoma is a pediatric cancer that is frequently metastatic and resistant to conventional treatment. In part, a lack of natively metastatic, chemoresistant in vivo models has limited our insight into the development ...
• Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response. 

  Libertini, M; Mitra, I; van der Graaf, WTA; Miah, AB; Judson, I; Jones, RL; Thomas, K; Moskovic, E; Szucs, Z; Benson, C; Messiou, C (2018)

  Background: One of the commonly used systemic agents for the treatment of aggressive fibromatosis is the anti-oestrogen drug tamoxifen. However, data on efficacy and optimum methods of response assessment are limited, ...
• The International Penile Advanced Cancer Trial (InPACT): Rationale and Current Status 

  Canter, DJ; Nicholson, S; Watkin, N; Hall, E; Pettaway, C (Elsevier BV, 2019-06)
• p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance. 

  Yogev, O; Barker, K; Sikka, A; Almeida, GS; Hallsworth, A; Smith, LM; Jamin, Y; Ruddle, R; Koers, A; Webber, HT; Raynaud, FI; Popov, S; Jones, C; Petrie, K; Robinson, SP; Keun, HC; Chesler, L (2016-05)

  Neuroblastoma is the most common childhood extracranial solid tumor. In high-risk cases, many of which are characterized by amplification of MYCN, outcome remains poor. Mutations in the p53 (TP53) tumor suppressor are rare ...
• Investigating the Contribution of Collagen to the Tumor Biomechanical Phenotype with Non-invasive Magnetic Resonance Elastography. 

  Li, J; Zormpas-Petridis, K; Boult, JK; Reeves, EL; Heindl, A; Vinci, M; Lopes, F; Cummings, C; Springer, CJ; Chesler, L; Jones, C; Bamber, JC; Yuan, Y; Sinkus, R; Jamin, Y; Robinson, SP (2019-10-11)

  Increased stiffness in the extracellular matrix (ECM) contributes to tumor progression and metastasis. Therefore, stromal modulating therapies and accompanying biomarkers are being developed to target ECM stiffness. Magnetic ...
• Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. 

  Camidge, DR; Kim, HR; Ahn, M-J; Yang, JC-H; Han, J-Y; Lee, J-S; Hochmair, MJ; Li, JY-C; Chang, G-C; Lee, KH; Gridelli, C; Delmonte, A; Garcia Campelo, R; Kim, D-W; Bearz, A; Griesinger, F; Morabito, A; Felip, E; Califano, R; Ghosh, S; Spira, A; Gettinger, SN; Tiseo, M; Gupta, N; Haney, J; Kerstein, D; Popat, S (2018-11-22)

  BACKGROUND: Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is refractory to crizotinib. The efficacy of ...
• Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. 

  Mazières, J; Drilon, A; Lusque, A; Mhanna, L; Cortot, AB; Mezquita, L; Thai, AA; Mascaux, C; Couraud, S; Veillon, R; Van Den Heuvel, M; Neal, J; Peled, N; Früh, M; Ng, TL; Gounant, V; Popat, S; Diebold, J; Sabari, J; Zhu, VW; Rothschild, SI; Bironzo, P; Martinez, A; Curioni-Fontecedro, A; Rosell, R; Lattuca-Truc, M; Wiesweg, M; Besse, B; Solomon, B; Barlesi, F; Schouten, RD; Wakelee, H; Camidge, DR; Zalcman, G; Novello, S; Ou, SI; Milia, J; Gautschi, O (2019-05-24)

  BACKGROUND: Anti-PD1/PD-L1 directed immune-checkpoint-inhibitors (ICI) are widely used to treat patients with advanced non-small cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations ...
• De novo phosphatidylcholine synthesis is required for autophagosome membrane formation and maintenance during autophagy. 

  Andrejeva, G; Gowan, S; Lin, G; Wong Te Fong, A-CL; Shamsaei, E; Parkes, HG; Mui, J; Raynaud, FI; Asad, Y; Vizcay-Barrena, G; Nikitorowicz-Buniak, J; Valenti, M; Howell, L; Fleck, RA; Martin, L-A; Kirkin, V; Leach, MO; Chung, Y-L (2019-09-13)

  Macroautophagy/autophagy can enable cancer cells to withstand cellular stress and maintain bioenergetic homeostasis by sequestering cellular components into newly formed double-membrane vesicles destined for lysosomal ...
• Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. 

  Brand, DH; Tree, AC; Ostler, P; van der Voet, H; Loblaw, A; Chu, W; Ford, D; Tolan, S; Jain, S; Martin, A; Staffurth, J; Camilleri, P; Kancherla, K; Frew, J; Chan, A; Dayes, IS; Henderson, D; Brown, S; Cruickshank, C; Burnett, S; Duffton, A; Griffin, C; Hinder, V; Morrison, K; Naismith, O; Hall, E; van As, N; PACE Trial Investigators (2019-09-17)

  BACKGROUND: Localised prostate cancer is commonly treated with external-beam radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional fractionation. Ultra-hypofractionated stereotactic ...
• Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers. 

  Rescigno, P; Lorente, D; Dolling, D; Ferraldeschi, R; Rodrigues, DN; Riisnaes, R; Miranda, S; Bianchini, D; Zafeiriou, Z; Sideris, S; Ferreira, A; Figueiredo, I; Sumanasuriya, S; Mateo, J; Perez-Lopez, R; Sharp, A; Tunariu, N; de Bono, JS (2018-05)

  Background: Loss of PTEN is a common genomic aberration in castration-resistant prostate cancer (CRPC) and is frequently concurrent with ERG rearrangements, causing resistance to next-generation hormonal treatment (NGHT) ...
• Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. 

  Sumanasuriya, S; Omlin, A; Armstrong, A; Attard, G; Chi, KN; Bevan, CL; Shibakawa, A; IJzerman, MJ; De Laere, B; Lolkema, M; Lorente, D; Luo, J; Mehra, N; Olmos, D; Scher, H; Soule, H; Stoecklein, NH; Terstappen, LWMM; Waugh, D; de Bono, JS (2018-06)

  CONTEXT: In advanced prostate cancer (PC), there is increasing investigation of circulating biomarkers, including quantitation and characterization of circulating tumour cells and cell-free nucleic acids, for therapeutic ...
• CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. 

  Zimmermann, M; Murina, O; Reijns, MAM; Agathanggelou, A; Challis, R; Tarnauskaitė, Ž; Muir, M; Fluteau, A; Aregger, M; McEwan, A; Yuan, W; Clarke, M; Lambros, MB; Paneesha, S; Moss, P; Chandrashekhar, M; Angers, S; Moffat, J; Brunton, VG; Hart, T; de Bono, J; Stankovic, T; Jackson, AP; Durocher, D (2018-07)

  The observation that BRCA1- and BRCA2-deficient cells are sensitive to inhibitors of poly(ADP-ribose) polymerase (PARP) has spurred the development of cancer therapies that use these inhibitors to target deficiencies in ...
• A decade of clinical development of PARP inhibitors in perspective. 

  Mateo, J; Lord, CJ; Serra, V; Tutt, A; Balmaña, J; Castroviejo-Bermejo, M; Cruz, C; Oaknin, A; Kaye, SB; de Bono, JS (2019-09-01)

  Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair capacities in tumour cells. DNA damage repair defects are common in different cancer types; these alterations can also induce ...
• A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. 

  O'Brien, MER; Sarker, D; Bhosle, J; Thillai, K; Yap, TA; Uttenreuther-Fischer, M; Pemberton, K; Jin, X; Wiebe, S; de Bono, J; Spicer, J (2018-11)

  PURPOSE: Afatinib, an irreversible ErbB family blocker, has demonstrated preclinical antitumor activity with chemotherapy. METHODS: As part of a phase I trial in patients with advanced solid tumors (NCT00809133; 3 + 3 ...
• Surrogate endpoints in advanced sarcoma trials: a meta-analysis. 

  Savina, M; Litière, S; Italiano, A; Burzykowski, T; Bonnetain, F; Gourgou, S; Rondeau, V; Blay, J-Y; Cousin, S; Duffaud, F; Gelderblom, H; Gronchi, A; Judson, I; Le Cesne, A; Lorigan, P; Maurel, J; van der Graaf, W; Verweij, J; Mathoulin-Pélissier, S; Bellera, C (2018-10-02)

  Background: Alternative endpoints to overall survival (OS) are frequently used to assess treatment efficacy in randomized controlled trials (RCT). Their properties in terms of surrogate outcomes for OS need to be assessed. ...
• Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. 

  Cesne, AL; Bauer, S; Demetri, GD; Han, G; Dezzani, L; Ahmad, Q; Blay, J-Y; Judson, I; Schöffski, P; Aglietta, M; Hohenberger, P; Gelderblom, H (2019-08-13)

  BACKGROUND: PALETTE is a phase 3 trial that demonstrated single-agent activity of pazopanib in advanced soft tissue sarcomas (aSTS). We performed retrospective subgroup analyses to explore potential relationships between ...
• When to keep it simple - adaptive designs are not always useful. 

  Wason, JMS; Brocklehurst, P; Yap, C (2019-08-02)

  BACKGROUND: Adaptive designs are a wide class of methods focused on improving the power, efficiency and participant benefit of clinical trials. They do this through allowing information gathered during the trial to be used ...

View more